MARCOS DANILLO PEIXOTO OLIVEIRA

Índice h a partir de 2011
2
ResearcherID
ORCID
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Coração, Hospital das Clínicas, Faculdade de Medicina - Médico

Filtros

Limpar filtros

Configurações

search.filters.applied.f.dateIssued: 2015 ×

Resultados de Busca

Agora exibindo 1 - 4 de 4
  • article
    Type 4 Dual Left Anterior Descending Artery: A Very Rare Coronary Anomaly Circulation
    (2015) OLIVEIRA, Marcos Danillo Peixoto; MELO, Pedro H. M. Craveiro de; ESTEVES FILHO, Antonio; KAJITA, Luiz J.; RIBEIRO, Expedito E.; LEMOS, Pedro Alves
    Coronary artery anomalies are congenital changes in their origin, course, and/or structure. They are the second most frequent cause of sudden death in young athletes. Dual LAD artery is a rare coronary anomaly. We present the case of a 44-year-old man with recent onset exertional angina and documented ischemia whose coronary angiogramand computed tomography (CT) showed type 4 dual LAD artery, the rarest and most interesting variant.
  • article
    Left Main Compression by a Giant Aneurysm of the Left Sinus of Valsalva: An Extremely Rare Reason for Myocardial Infarction and Cardiogenic Shock
    (2015) FAILLACE, Bruno L. R.; GALON, Micheli Z.; OLIVEIRA, Marcos Danillo P.; PRADO JR., Guy F. A.; TRUFFA, Adriano A. M.; RIBEIRO, Expedito E.; LEMOS, Pedro A.
    Aneurysms of the sinus of Valsalva are very rare and mostly located in the right coronary sinus. They might course with dyspnea, fatigue, and acute coronary syndromes. We present herein an extremely rare case report of a 61-year-old woman diagnosed with external left main coronary compression by a giant aneurysm of the left sinus of Valsalva, which was successfully managed with percutaneous coronary intervention.
  • article 6 Citação(ões) na Scopus
    Superdominant Right Coronary Artery with Absence of Left Circumflex and Anomalous Origin of the Left Anterior Descending Coronary from the Right Sinus: An Unheard Coronary Anomaly Circulation
    (2015) OLIVEIRA, Marcos Danillo Peixoto; FAZZIO, Fernando Roberto de; MARIANI JUNIOR, Jose; CAMPOS, Carlos M.; KAJITA, Luiz Junya; RIBEIRO, Expedito E.; LEMOS, Pedro Alves
    Coronary artery anomalies are congenital changes in their origin, course, and/or structure. Most of them are discovered as incidental findings during coronary angiographic studies or at autopsies. We present herein the case of a 70-year-old man with symptomatic severe aortic valvar stenosis whose preoperative coronary angiogram revealed a so far unreported coronary anomaly circulation pattern.
  • article
    Four-year clinical follow-up of the first-in-man randomized comparison of a novel sirolimus eluting stent with abluminal biodegradable polymer and ultra-thin strut cobalt-chromium alloy: the INSPIRON-I trial
    (2015) OLIVEIRA, Marcos Danillo Peixoto; RIBEIRO, Expedito E.; CAMPOS, Carlos M.; RIBEIRO, Henrique B.; FAILLACE, Bruno L. R.; LOPES, Augusto C.; ESPER, Rodrigo B.; MEIRELLES, George X.; PERIN, Marco A.; ABIZAID, Alexandre; LEMOS, Pedro A.
    Background: The Inspiron (TM) sirolimus-eluting stent (SES) is a low-dose, ultra-thin-strut cobalt-chromium stent abluminally coated with biodegradable polymers (BP). Previous results from the INSPIRON-I trial, a first-in-man study, have proven the efficacy of the novel stent in reducing neointimal proliferation. The present report aims at evaluating the long-term clinical outcomes of patients enrolled into the INSPIRON-I trial (Clinical Trials Gov. identifier: NCT01093391). Methods: A total of 57 patients (60 lesions) were randomly allocated in a 2: 1 ratio to treatment with the Inspiron (TM) SES vs. its equivalent Cronus (TM) bare metal stent (BMS, both by Scitech Medical (TM), Aparecida de Goiania, Goias, Brazil), in four tertiary centers. The primary endpoint of the present analysis was the occurrence of major adverse cardiac events (MACE) [death, myocardial infarction (MI), target vessel revascularization (TVR) and/or target lesion revascularization (TLR)] at 4 years. Results: Baseline clinical and angiographic characteristics of both groups were similar. After 4 years, the primary endpoint occurred in 7.9% vs. 23.5% of patients in Inspiron and control groups respectively (P=0.11). The rate of death/MI was similar between the groups, but there was a significant decrease in the risk of repeat revascularization in the Inspiron group compared to the control arm TLR (0.0% vs. 23.5% respectively, P= 0.02). There were no stent thromboses in the study population. Conclusions: The novel Inspiron (TM) SES showed a sustained safe and effective clinical profile after 4-year of follow-up, with very low adverse events and null stent thrombosis (ST) occurrence.